Topic
Pay for Delay
47 published works
Focus on Regulation
FTC Closes Seven-Year Adderall XR Pay-for-Delay Investigation
Last week the FTC announced that it was closing its investigation of patent settlement agreements between Shire Laboratories, Barr Pharmaceuticals, and Impax Laboratories related to Adderall XR without taking action. …
Inside EU Life Sciences
Lundbeck: First European Commission Decision on “Pay for Delay”
On 19 June 2013, the European Commission imposed fines totaling EUR 146 million to Lundbeck and several producers of generic medicines, including Alpharma, Merck KGaA/Generics UK, Arrow, and Ranbaxy, for…
Health Law Update
Supreme Court Rules That “Pay for Delay” Generic Drug Patent Settlements Aren’t Shielded From Antitrust Liability
By Jonathan Lewis, Lee Simowitz
The U.S. Supreme Court has held that the antitrust laws may forbid patent settlements that delay the market entry of generic drugs in return for large payments from manufacturers of…
The Brand Protection Blog
US Supreme Court holds pay-for-delay subject to antitrust scrutiny but not presumptively unlawful
By Layne Kruse (US), Darryl Anderson (US)
The fight to curtail “pay-for-delay” or “reverse payment” settlements between pharmaceutical patent holders and generic drug makers received a shot in the arm on Monday, as the Supreme Court held…
Global Regulatory Enforcement Law Blog
Supreme Court Remands Pay-for-Delay Settlement for Antitrust Review in FTC v. Actavis
By P. Gavin Eastgate, William J. Sheridan
This post was also written by Jessica R. Rose. The U.S. Supreme Court last week issued a significant decision subjecting pay-for-delay settlements, a common practice in the pharmaceutical industry, to antitrust…
ContractsProf Blog
Pay-to-Delay Agreements and the Supremes
On Monday, the U.S. Supreme Court issued a ruling in Federal Trade Commission v. Actavis that permitted the Federal Trade Commission to sue pharmaceutical companies for potential antitrust violations when…
Health Law Rx
Supreme Court Rules Pharmaceutical “Pay For Delay” Agreements Are Subject to Anti-Trust Review
The Supreme Court struck a blow for consumers when it ruled the Federal Trade Commission may file suit to prevent pharmaceutical companies from agreeing to pay generic drug manufacturers to…
Mass Torts Law Blog
Pharmaceutical Companies Provide Compensation to Generic Drug Makers
Pharmaceutical companies frequently pay generic drug competitors money to delay releasing their cheaper versions of brand-name drugs. The result is a large financial reward for the pharmaceutical companies, both name…
Antitrust, Competition and Trade
Supreme Court Hears Arguments on “Pay for Delay” Agreements
On March 25, 2012, the Supreme Court heard oral argument on the legality of “reverse payment” or “pay for delay” agreements between brand-name and generic drug manufacturers. Reverse payment agreements…
Antitrust Alert
Supreme Court Hears Oral Argument in “Pay-for-Delay” Patent Settlement Antitrust Case
by Jeffrey Brennan and Glenn Engelmann The Supreme Court’s ruling in Federal Trade Commission v. Actavis, Inc., will almost certainly have major implications for the viability of Federal Trade Commission…